Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eisuke Adachi

Showing results (101-110 of 118) with videos related to

Pageof 12
Sort By:
Anticancer Research|April 30, 2016
Surgical Results of Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: a Multi-institutional Retrospective Study of 174 patientsYo-Ichi Yamashita, Tomoharu Yoshizumi, Kengo Fukuzawa, et al.
AIDS Patient Care and Stds|January 10, 2023
Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical TrialTahilin Sanchez Karver, Miguel Pascual-Bernaldez, Alessandro Berni, et al.
AIDS and Behavior|October 7, 2024
Improvements in Patient-Reported Outcomes After 12 Months of Maintenance Therapy With Cabotegravir + Rilpivirine Long-Acting Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide in the Phase 3b SOLAR StudyCristina Mussini, Charles Cazanave, Eisuke Adachi, et al.
Microbiology Spectrum|August 11, 2021
Unique Gut Microbiome in HIV Patients on Antiretroviral Therapy (ART) Suggests Association with Chronic InflammationAya Ishizaka, Michiko Koga, Taketoshi Mizutani, et al.
Iscience|October 25, 2023
Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolateRyuta Uraki, Mutsumi Ito, Maki Kiso, et al.
Viruses|February 28, 2023
Characterization of Influenza A(H1N1)pdm09 Viruses Isolated in the 2018-2019 and 2019-2020 Influenza Seasons in JapanTakuma Soga, Calvin Duong, David Pattinson, et al.
Science Advances|March 6, 2021
Longitudinal antibody repertoire in "mild" versus "severe" COVID-19 patients reveals immune markers associated with disease severity and resolutionSupriya Ravichandran, Youri Lee, Gabrielle Grubbs, et al.
Iscience|July 14, 2023
Differences among epitopes recognized by neutralizing antibodies induced by SARS-CoV-2 infection or COVID-19 vaccinationShinya Yamamoto, Seiya Yamayoshi, Mutsumi Ito, et al.
The Journal of Infectious Diseases|December 22, 2022
Antibody Avidity Maturation Following Recovery From Infection or the Booster Vaccination Grants Breadth of SARS-CoV-2 Neutralizing CapacityYu Nakagama, Katherine Candray, Natsuko Kaku, et al.
Nature Microbiology|November 27, 2019
Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory dropletsMasaki Imai, Makoto Yamashita, Yuko Sakai-Tagawa, et al.
Pageof 12

Showing results (101-110 of 118) with videos related to

Sort By:
Pageof 12
Anticancer Research|April 30, 2016
Surgical Results of Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: a Multi-institutional Retrospective Study of 174 patientsYo-Ichi Yamashita, Tomoharu Yoshizumi, Kengo Fukuzawa, et al.
AIDS Patient Care and Stds|January 10, 2023
Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical TrialTahilin Sanchez Karver, Miguel Pascual-Bernaldez, Alessandro Berni, et al.
AIDS and Behavior|October 7, 2024
Improvements in Patient-Reported Outcomes After 12 Months of Maintenance Therapy With Cabotegravir + Rilpivirine Long-Acting Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide in the Phase 3b SOLAR StudyCristina Mussini, Charles Cazanave, Eisuke Adachi, et al.
Microbiology Spectrum|August 11, 2021
Unique Gut Microbiome in HIV Patients on Antiretroviral Therapy (ART) Suggests Association with Chronic InflammationAya Ishizaka, Michiko Koga, Taketoshi Mizutani, et al.
Iscience|October 25, 2023
Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolateRyuta Uraki, Mutsumi Ito, Maki Kiso, et al.
Viruses|February 28, 2023
Characterization of Influenza A(H1N1)pdm09 Viruses Isolated in the 2018-2019 and 2019-2020 Influenza Seasons in JapanTakuma Soga, Calvin Duong, David Pattinson, et al.
Science Advances|March 6, 2021
Longitudinal antibody repertoire in "mild" versus "severe" COVID-19 patients reveals immune markers associated with disease severity and resolutionSupriya Ravichandran, Youri Lee, Gabrielle Grubbs, et al.
Iscience|July 14, 2023
Differences among epitopes recognized by neutralizing antibodies induced by SARS-CoV-2 infection or COVID-19 vaccinationShinya Yamamoto, Seiya Yamayoshi, Mutsumi Ito, et al.
The Journal of Infectious Diseases|December 22, 2022
Antibody Avidity Maturation Following Recovery From Infection or the Booster Vaccination Grants Breadth of SARS-CoV-2 Neutralizing CapacityYu Nakagama, Katherine Candray, Natsuko Kaku, et al.
Nature Microbiology|November 27, 2019
Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory dropletsMasaki Imai, Makoto Yamashita, Yuko Sakai-Tagawa, et al.
Pageof 12